Relmacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase I drugs for Systemic Sclerosis (Scleroderma) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Relmacabtagene autoleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Relmacabtagene autoleucel overview

Relmacabtagene Autoleuce (Carteyva) is an autologous anti-CD19 CAR-T cell immunotherapy drug. It is developed based on a CAR T cell process platform. It is formulated as solution for intravenous and parenteral route of administration. Carteyva is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

Relmacabtagene Autoleucel is under development for the treatment of relapsed and refractory B-cell non-Hodgkin Lymphomas including diffuse unspecified large B-cell lymphoma, mantle cell lymphoma,acute lymphocytic leukemia, diffuse large B-cell lymphoma, systemic sclerosis, marginal zone b-cell lymphoma, follicular lymphoma, systemic lupus erythematosus, primary mediastinal B-cell lymphoma and malignant hematoma. The therapeutic candidate consists of T cells engineered to express chimeric antigen receptors (CAR T-cells). It is administered through the intravenous route. It acts by targeting CD19 expressing cancer cells.

The drug candidate was under development for the treatment of chronic lymphocytic leukemia.

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company. It is engaged in the discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, immunology, cardiovascular, and fibrotic diseases. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. The company has an operational presence in the US, Switzerland, Puerto Rico, Ireland, and the Netherlands. The company conducts research to focus on the discovery and development of novel medicines that address diseases in areas of unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.

For a complete picture of Relmacabtagene autoleucel’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 12 April 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.